Human CTLA4-expressing Raji Cells

Human CTLA-4-expressing B cells

Raji-hCTLA4 cells were developed from the Raji cell line, a human B lymphocyte-derived cell line. Raji cells have been successfully used as target cells in CAR-T toxicity assays as well as in human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells.

CTLA-4 (cytotoxic T cell lymphocyte antigen-4; also known as CD152) is a type I transmembrane protein expressed at the cell surface of activated conventional T cells and constitutively on immunosuppressive regulatory T cells (Tregs). CTLA-4 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage. It exerts competitive binding for stimulatory CD28 ligands (CD80/CD86) [1].

Features of Raji-hCTLA4 cells:

• Stable overexpression of the human CTLA-4 gene
• Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
• Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL
• The stability for 20 passages following thawing has been verified

Applications for Raji-hCTLA4 cells:

• Target cell line for ADCC assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells
• Target cell line for cell toxicity assays using NK or CAR-T cells
• For use in the development of other functional assays

Validation of Raji-hCTLA4 cells:

• Overexpression of CTLA-4 verified by flow cytometry
• Functionally tested as target cells in ADCC assays using anti-human CTLA-4 monoclonal Abs and Jurkat-Lucia™ NFAT-CD16 cells
• Guaranteed mycoplasma-free

References:

1. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.